DK1644340T3 - N-[ ( { ' 4-substitueret piperazin-1-yl } sulfonylmethyl ) alkyl ] -N-hydroxyformamidforbindelser som metalloproteinaseinhibitorer - Google Patents

N-[ ( { ' 4-substitueret piperazin-1-yl } sulfonylmethyl ) alkyl ] -N-hydroxyformamidforbindelser som metalloproteinaseinhibitorer

Info

Publication number
DK1644340T3
DK1644340T3 DK04743053T DK04743053T DK1644340T3 DK 1644340 T3 DK1644340 T3 DK 1644340T3 DK 04743053 T DK04743053 T DK 04743053T DK 04743053 T DK04743053 T DK 04743053T DK 1644340 T3 DK1644340 T3 DK 1644340T3
Authority
DK
Denmark
Prior art keywords
sulfonylmethyl
alkyl
metalloproteinase inhibitors
substituted piperazin
hydroxyformamide
Prior art date
Application number
DK04743053T
Other languages
Danish (da)
English (en)
Inventor
Maurice R V Finlay
David Waterson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1644340(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1644340T3 publication Critical patent/DK1644340T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK04743053T 2003-06-27 2004-06-23 N-[ ( { ' 4-substitueret piperazin-1-yl } sulfonylmethyl ) alkyl ] -N-hydroxyformamidforbindelser som metalloproteinaseinhibitorer DK1644340T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds
PCT/GB2004/002702 WO2005000822A1 (en) 2003-06-27 2004-06-23 N-{‘4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
DK1644340T3 true DK1644340T3 (da) 2009-02-02

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04743053T DK1644340T3 (da) 2003-06-27 2004-06-23 N-[ ( { ' 4-substitueret piperazin-1-yl } sulfonylmethyl ) alkyl ] -N-hydroxyformamidforbindelser som metalloproteinaseinhibitorer

Country Status (34)

Country Link
US (1) US7485644B2 (es)
EP (1) EP1644340B1 (es)
JP (1) JP4701167B2 (es)
KR (1) KR20060026440A (es)
CN (2) CN102229589A (es)
AR (1) AR044931A1 (es)
AT (1) ATE414063T1 (es)
AU (1) AU2004251104B2 (es)
BR (1) BRPI0411929A (es)
CA (1) CA2529468A1 (es)
CO (1) CO5650254A2 (es)
CY (1) CY1108757T1 (es)
DE (1) DE602004017733D1 (es)
DK (1) DK1644340T3 (es)
ES (1) ES2315675T3 (es)
HK (1) HK1086835A1 (es)
HR (1) HRP20090009T3 (es)
IL (1) IL172615A0 (es)
IS (1) IS8257A (es)
MX (1) MXPA05013460A (es)
MY (1) MY138680A (es)
NO (1) NO20060444L (es)
NZ (1) NZ544208A (es)
PL (1) PL1644340T3 (es)
PT (1) PT1644340E (es)
RU (1) RU2351595C2 (es)
SA (1) SA04250224B1 (es)
SE (1) SE0301922D0 (es)
SI (1) SI1644340T1 (es)
TW (1) TW200524898A (es)
UA (1) UA81491C2 (es)
UY (1) UY28387A1 (es)
WO (1) WO2005000822A1 (es)
ZA (1) ZA200510458B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
DK1951674T3 (da) * 2005-10-26 2012-01-02 Merck Serono Sa Sulfonamidderivater og anvendelse deraf til modulation af metalloproteinaser
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
ES2592154T3 (es) * 2010-07-08 2016-11-28 Kaken Pharmaceutical Co., Ltd. Derivado de N-hidroxiformamida y medicamento que contiene el mismo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2317455C (en) 1998-01-30 2011-01-25 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
JP2003501414A (ja) * 1999-06-04 2003-01-14 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼの阻害剤
UA73155C2 (en) * 2000-02-21 2005-06-15 Astrazeneca Ab Substituted by piperidine and piperazine n-hydroxyformamides as metalloproteinase inhibitors
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
AU2003221786A1 (en) * 2002-04-25 2003-11-10 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
WO2004113312A1 (en) * 2003-06-19 2004-12-29 Celltech R & D Limited Hydroxamate sulfonamides as cd23 shedding inhibitors

Also Published As

Publication number Publication date
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
AU2004251104A1 (en) 2005-01-06
ATE414063T1 (de) 2008-11-15
HRP20090009T3 (en) 2009-02-28
JP2007516164A (ja) 2007-06-21
MXPA05013460A (es) 2006-03-09
JP4701167B2 (ja) 2011-06-15
NO20060444L (no) 2006-03-22
ZA200510458B (en) 2007-03-28
PL1644340T3 (pl) 2009-04-30
PT1644340E (pt) 2009-01-02
RU2005141058A (ru) 2006-07-27
US7485644B2 (en) 2009-02-03
CO5650254A2 (es) 2006-06-30
KR20060026440A (ko) 2006-03-23
MY138680A (en) 2009-07-31
US20070197542A1 (en) 2007-08-23
UA81491C2 (en) 2008-01-10
WO2005000822A1 (en) 2005-01-06
SE0301922D0 (sv) 2003-06-27
EP1644340B1 (en) 2008-11-12
CA2529468A1 (en) 2005-01-06
CY1108757T1 (el) 2014-04-09
RU2351595C2 (ru) 2009-04-10
AR044931A1 (es) 2005-10-12
CN1812974B (zh) 2011-06-29
AU2004251104B2 (en) 2008-05-08
TW200524898A (en) 2005-08-01
HK1086835A1 (en) 2006-09-29
BRPI0411929A (pt) 2006-08-15
CN102229589A (zh) 2011-11-02
ES2315675T3 (es) 2009-04-01
SI1644340T1 (sl) 2009-02-28
DE602004017733D1 (de) 2008-12-24
UY28387A1 (es) 2005-01-31
CN1812974A (zh) 2006-08-02
IL172615A0 (en) 2006-04-10
EP1644340A1 (en) 2006-04-12
IS8257A (is) 2006-01-23

Similar Documents

Publication Publication Date Title
CY2016042I2 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
DK1542977T3 (da) 2,5-dioxoimidazolidin-4-ylacetamider og analoger som inhibitorer af metalloproteinase MMP12
NL1027811A1 (nl) Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.
DK1485365T3 (da) Sulfonyl-derivater som nye inhibitorer af histandeacetylase
DK1436271T6 (da) Phenylpiperazinderivater som serotonin-genoptagelseshæmmere
NO20043726L (no) Heteroarylforbindelser anvendelige som inhibitorer av GSK-3
SE0701538L (sv) Azaspiroalkanderivat som hämmare av metalloproteaser
NO20031540D0 (no) Benzamidforbindelser som Apo-B-sekresjonsinhibitorer
DK1485348T3 (da) Carbonylamino-derivater som nye inhibitorer af histandeacetylase
DK1485354T3 (da) Sulfonylamino-derivater som nye inhibitorer af histandeacetylase
DK1611112T3 (da) Isoxazolforbindelser som hæmmere af varmechokproteiner
DE602005011795D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DK2039685T3 (da) Heterobicycliske forbindelser som P38-inhibitorer
DK1651621T3 (da) 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer
DK1482932T3 (da) N3-alkylerede benzimidazolderivater som MEK-inhibitorer
NO20033618L (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
DK1401828T3 (da) N-Formylhydroxylaminforbindelser som inhibitorer af PDF
NO20040996L (no) Nye forbindelser og sammensetninger som catepsin-inhibitorer
DK1536796T3 (da) N-arylpiperidinsubstituerede biphenylcarboxamider som inhibitorer af apolipoprotein B-sektion
IS7585A (is) Ný piperadín efnasambönd
HK1086835A1 (en) N-[({'4-substituted piperazine-1-y}sulfonylmethyl)alkyl]-n-hxdroxyformamide compounds as metallopro teinase inhibitors
MA28811B1 (fr) Nouvelles utilisations de derives d'imidazotriazinones substituees par 2-phenyle
WO2004099124A3 (de) Neue bioisostere von actinonin
DK1637141T3 (da) Stabiliseret proteasesammensætning omfattende en serinprotease, morpholinderivater og reversible inhibitorer af serinproteasen